8-K: Tempest Therapeutics Secures $2M in Private Placement

Tempest Therapeutics, Inc. announced a private placement of common stock and warrants, raising $2.0 million initially with potential for an additional $4.0 million.

Summary

• Tempest Therapeutics entered into a Securities Purchase Agreement on March 20, 2026, for a private placement with two institutional investors and Factor Bioscience Inc. (Strategic Investor).
• The company will issue an aggregate of 462,964 shares of common stock and, in lieu of common stock, pre-funded warrants to purchase up to 462,963 shares of common stock.
• The placement also includes Series A warrants to purchase up to 925,927 shares of common stock and Series B warrants to purchase up to 925,927 shares of common stock.
• The combined purchase price is $2.16 per share of common stock and accompanying common warrants, and $2.159 per pre-funded warrant and accompanying common warrants.
• Gross proceeds are expected to be approximately $2.0 million from the private placement, with potential for up to an additional $4.0 million upon the cash exercise of the Common Warrants.
• Net proceeds from the private placement are planned for working capital and general corporate purposes.
• The closing of the private placement is expected on or about March 23, 2026.
• Pre-funded warrants are immediately exercisable at a nominal exercise price of $0.001 per share and expire when exercised in full.
• Common Warrants (Series A and B) have an exercise price of $2.16 per share and become exercisable on the effective date of stockholder approval.
• The company has agreed to seek stockholder approval for the issuance of shares underlying the Common Warrants within 90 days following the date of the Purchase Agreement.
• A 30-day lock-up period applies to the company, restricting the sale of certain equity securities after the registration statement's effectiveness date, subject to customary exceptions.
• H.C. Wainwright & Co., LLC served as the exclusive placement agent, receiving a 6.0% cash fee for proceeds from institutional investors and a 3.0% cash fee for proceeds from the Strategic Investor.
• A Registration Rights Agreement was also executed, obligating the company to file a registration statement for the resale of the shares and warrant shares within 15 calendar days and use best efforts to have it declared effective within 45 calendar days (or 75 days for full SEC review).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, as it secures immediate capital and potential future funding, but the significant potential dilution from the warrants and the need for stockholder approval introduce elements of uncertainty and risk for existing shareholders.

Positives

• Successfully secured approximately $2.0 million in immediate gross proceeds, providing capital for working capital and general corporate purposes.
• The private placement has the potential to generate up to an additional $4.0 million in gross proceeds upon the cash exercise of the Common Warrants.
• The participation of Factor Bioscience Inc. as a 'Strategic Investor' may signal confidence in the company's long-term prospects or strategic alignment.
• Pre-funded warrants offer immediate exercisability at a nominal price, providing investors with flexibility.
• Registration rights granted to investors facilitate future liquidity for their purchased securities.

Negatives

• The issuance of common stock and warrants carries a significant potential for dilution for existing shareholders.
• The exercisability of the Common Warrants is contingent upon obtaining stockholder approval, introducing a potential delay and uncertainty for investors.
• Placement agent fees of 6.0% and 3.0% reduce the net proceeds received by the company from the private placement.
• The company is subject to a 30-day lock-up period on certain equity sales after the registration statement's effectiveness, which could limit immediate financing flexibility.

Risks

• Failure to obtain stockholder approval for the issuance of shares underlying the Common Warrants could impact investor rights and the company's financing strategy.
• Significant dilution from the exercise of warrants could negatively impact the per-share value for existing shareholders.
• Market price volatility could affect the value of the warrants and the likelihood of their exercise, potentially reducing the additional capital raised.
• Delays in the effectiveness of the registration statement could limit investors' ability to resell securities, potentially leading to liquidated damages for the company.
• The company's ability to maintain its listing on the Nasdaq Stock Market LLC is crucial for investor liquidity and market access.

Future Outlook

The company plans to use the net proceeds from this private placement for working capital and general corporate purposes. Key near-term milestones include the closing of the private placement, timely filing and effectiveness of the registration statement for resale of the securities, and obtaining stockholder approval for the common warrants, all of which are crucial for investor liquidity and the full realization of potential capital.

Management Comments

• The company currently plans to use the net proceeds from the Private Placement primarily for working capital and general corporate purposes.
• The company agreed to seek approval from its stockholders for the issuance of the shares issuable upon exercise of the Common Warrants within 90 days following the date of the Purchase Agreement.
• The company has agreed not to sell any shares of Common Stock or any securities convertible into or exercisable or exchangeable into shares of Common Stock, subject to certain customary exceptions, for a period of thirty (30) days after the Effectiveness Date.

Industry Context

StockSavvy.ai notes that private placements are a common financing strategy for biotechnology and pharmaceutical companies like Tempest Therapeutics, especially those in clinical development stages, to secure capital without the extensive regulatory requirements and market volatility associated with public offerings. The participation of a 'Strategic Investor' such as Factor Bioscience Inc. could signal a vote of confidence in Tempest's pipeline or technology, potentially differentiating this raise from pure financial investments. However, the significant warrant coverage and the need for stockholder approval for common warrants are typical features that can lead to substantial dilution for existing shareholders, a common concern in the high-burn-rate biotech sector.

Comparison to Industry Standards

• The combined purchase price of $2.16 per share and accompanying warrants is within the typical range for private placements in the biotech sector, often reflecting a discount to the prevailing market price to attract investors.
• The warrant coverage (100% for both Series A and Series B warrants) is relatively high, indicating a strong incentive for investors and potentially significant future dilution, which is not uncommon in early to mid-stage biotech financing rounds where risk is higher.
• The placement agent fees of 6.0% for institutional investors and 3.0% for the strategic investor are standard for such transactions, aligning with typical industry compensation structures for capital raises of this size.
• The 30-day lock-up period for the company is a common provision to stabilize the market post-offering, though some deals may feature longer or shorter restrictions depending on market conditions and investor demand.
• The requirement for stockholder approval for warrant exercisability is a standard corporate governance measure to comply with exchange listing rules (e.g., Nasdaq) regarding potential dilution exceeding certain thresholds.

Corporate Governance

Related Party Transactions

• Factor Bioscience Inc. is identified as a 'Strategic Investor' in this private placement and is also referenced in connection with a 'funding commitment letter, dated November 19, 2025' and an 'Asset Purchase Agreement', indicating an ongoing relationship.

Stakeholder Impact

• Shareholders: Potential for significant dilution from the issuance of new shares and the exercise of warrants, which will decrease existing shareholders' ownership percentage.
• Investors (Purchasers in Private Placement): Gain equity and warrant positions, with registration rights for liquidity. Pre-funded warrants offer immediate exercisability, while common warrants provide upside potential contingent on stockholder approval.
• Company: Receives immediate capital for operations and potential future capital upon warrant exercise, but incurs obligations related to registration and stockholder approval.

Next Steps

• Closing of the Private Placement on or about March 23, 2026.
• Company to file a registration statement for the resale of the Shares and Warrant Shares within 15 calendar days of March 20, 2026.
• Company to use best efforts to have the registration statement declared effective within 45 calendar days (or 75 days for full SEC review) of March 20, 2026.
• Company to seek stockholder approval for the issuance of shares underlying the Common Warrants within 90 days of March 20, 2026.
• Company to use net proceeds for working capital and general corporate purposes.

Key Dates

Recommendation

The capital raise provides necessary funding for Tempest Therapeutics, which is a positive for its operational continuity. However, the significant potential for dilution from the warrants, coupled with the requirement for stockholder approval for the common warrants, introduces considerable uncertainty. Investors should hold to monitor the outcome of the stockholder vote and the company's ability to effectively utilize the new capital to advance its strategic objectives, while being mindful of the dilutive impact.

Keywords

Tempest Therapeutics, Private Placement, Warrants, Common Stock, Capital Raise, SEC Filing, Equity Financing, Dilution, Stockholder Approval, Registration Rights, TPST, Biotechnology